MESENCHYMAL STEM CELL-DERIVED EXTRACELLULAR VESICLES AND THEIR MEDICAL USE

• US 20190328792A1
• Filed: 01/10/2018
• Published: 10/31/2019
• Est. Priority Date: 01/11/2017
• Status: Active Application

• Current Assignee: Paracelsus Medizinische Privatuniversitat Salzburg - Privatstiftung
• Original Assignee: Paracelsus Medizinische Privatuniversitat Salzburg - Privatstiftung
• Inventors: TRAWEGER, Andreas, GIMONA, Mario
• Application Number:
  US16/475,154
• Publication Number:
  US 20190328792A1
• Time in Patent Office: Days
• CPC Class Codes: A61K 2039/55555 Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61K 38/1841 Transforming growth factor [TGF]
• CPC Class Codes: A61K 47/6903 the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
• CPC Class Codes: A61P 19/04 for non-specific disorders of the connective tissue
• CPC Class Codes: A61P 19/08 for bone diseases, e.g. rachitism, Paget's disease
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: C07K 14/49 Platelet-derived growth factor [PDGF]
• CPC Class Codes: C07K 14/51 Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
• CPC Class Codes: C12N 15/111 General methods applicable to biologically active non-coding nucleic acids
• CPC Class Codes: C12N 15/113 Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing when used in plants C12N15/8218
• CPC Class Codes: C12N 15/1136 against growth factors, growth regulators, cytokines, lymphokines or hormones
• CPC Class Codes: C12N 2310/141 MicroRNAs, miRNAs
• CPC Class Codes: C12N 2320/30 Special therapeutic applications
• CPC Class Codes: C12N 2502/00 Coculture with; Conditioned medium produced by
• CPC Class Codes: C12N 2502/1358 Bone marrow mesenchymal stem cells (BM-MSC)
• CPC Class Codes: C12N 5/0663 Bone marrow mesenchymal stem cells (BM-MSC)

Abstract

The present invention relates to a method for obtaining extracellular vesicles derived from mesenchymal stromal cells (MSCs), wherein the extracellular-vesicles are essentially free of vesicles not derived from the MSCs, and wherein the extracellular-vesicles are essentially free of heparin. The invention further relates to the extracellular vesicles derived from mesenchymal stromal cells (MSCs), to a pharmaceutical composition comprising such extracellular-vesicles and to the use of the pharmaceutical composition in the treatment of (a) bone defect(s), tendon defect(s) and/or spinal cord injury. The pharmaceutical composition of the invention can further comprise one or more Bone Morphogenic Proteins (BMPs), such as BMP2.

Claims

1-53. -53. (canceled)

54. Pharmaceutical composition comprising extracellular-vesicles derived from mesenchymal stromal cells (MSCs), wherein the extracellular-vesicles are essentially free of vesicles not derived from the MSCs, and wherein the extracellular-vesicles are essentially free of heparin.

55. The pharmaceutical composition of claim 54, wherein the pharmaceutical composition comprises one or more Bone Morphogenic Proteins and/or PDGF, wherein the one or more Bone Morphogenic Protein(s) (BMP(s)) are selected from the group consisting of Bone Morphogenic Protein 2 (BMP2), Bone Morphogenic Protein 3 (BMP3), Bone Morphogenic Protein 4 (BMP4), Bone Morphogenic Protein 5 (BMP5), Bone Morphogenic Protein 6 (BMP6), Bone Morphogenic Protein 7 (BMP7), Bone Morphogenic Protein 8a (BMP8a), Bone Morphogenic Protein 8b (BMP8b), Bone Morphogenic Protein 12 (BMP12), Bone Morphogenic Protein 13 (BMP13), and Bone Morphogenic Protein 14 (BMP14).

56. The pharmaceutical composition of claim 54, wherein the pharmaceutical composition comprises BMP2.

57. The pharmaceutical composition of claim 54, wherein the pharmaceutical composition comprises BMP4.

58. The pharmaceutical composition of claim 54, wherein the pharmaceutical composition comprises BMP6.

59. The pharmaceutical composition of claim 54, wherein the pharmaceutical composition comprises BMP12.

60. The pharmaceutical composition of claim 54, wherein the pharmaceutical composition comprises BMP13.

61. The pharmaceutical composition of claim 54, wherein the pharmaceutical composition comprises BMP14.

62. The pharmaceutical composition of claim 54, wherein the pharmaceutical composition comprises a dose of the one or more BMP(s).

63. The pharmaceutical composition of claim 54, wherein the dose of the BMP(s) is between about 10 μ

g to about 10 mg.

65. The pharmaceutical composition of claim 54, wherein the pharmaceutical composition or the extracellular-vesicles is/are to be administered to the traumatic and/or disordered area.

66. The pharmaceutical composition of claim 54, wherein the vesicles not derived from the MSCs are vesicles that are comprised in a culture medium prior to the culturing of the MSCs, such as vesicles that are comprised in serum, human platelet lysate, or plasma.

67. The pharmaceutical composition of claim 54, wherein the vesicles not derived from the MSCs are vesicles that are comprised in a cell culture supplement, such as serum, human platelet lysate, or plasma.

68. The pharmaceutical composition of claim 54, wherein the extracellular-vesicles comprise at least about 80%, 85%, 90%, 94.4%, 95%, 99% or 99.5% of extracellular-vesicles derived from the MSCs.

69. The pharmaceutical composition of claim 54, wherein the extracellular-vesicles are essentially free of fibrinogen.

70. The pharmaceutical composition of claim 54, wherein the extracellular-vesicles are derived from MSCs cultured in culture medium that is essentially free of vesicles not derived from the MSCs and that is essentially free of heparin, and preferably fibrinogen, or wherein the extracellular-vesicles are derived from MSCs cultured in medium that is essentially free of cell culture supplement, such as serum, human platelet lysate, or plasma.

71. The pharmaceutical composition of claim 54, wherein the extracellular-vesicles are derived from MSCs cultured in culture medium, and wherein the fibrinogen and the vesicles were removed from the culture medium prior to the culturing of the MSCs, and preferably wherein said culture medium was supplemented with a cell culture supplement comprising vesicles.

72. The pharmaceutical composition of claim 54, wherein the extracellular-vesicles comprise hsa-miR-146a-5p, hsa-miR-92a-3p, hsa-miR-21-5p, hsa-miR-148a-3p, hsa-miR-221-3p, hsa-let-7i-5p, and hsa-let-7f-5p.

73. The pharmaceutical composition of claim 54, wherein the extracellular-vesicles are essentially free of hsa-miR-133, hsa-miR-135, hsa-miR-204, hsa-miR-211, hsa-miR-17, and hsa-miR-106.

74. The pharmaceutical composition of claim 54, wherein the extracellular-vesicles comprise:

100% of hsa-miR-146a-5p,

at least about 50% of hsa-miR-92a-3p,

at least about 15% of hsa-miR-21-5p,

at least about 10% of hsa-miR-148a-3p,

at least about 15% of hsa-miR-221-3p,

at least about 5% of hsa-let-7i-5p, and

at least about 5% of hsa-let-7f-5p,

wherein the level of hsa-miR-146a-5p is set to 100%.

75. The pharmaceutical composition of claim 54, wherein the extracellular-vesicles comprise:

100% of hsa-miR-146a-5p,

less than about 0.1% hsa-miR-133,

less than about 0.1% hsa-miR-135,

less than about 0.1% hsa-miR-204,

less than about 0.1% hsa-miR-211,

less than about 0.1% hsa-miR-17, and

less than about 0.1% hsa-miR-106,

wherein the level of hsa-miR-146a-5p is set to 100%.

76. The pharmaceutical composition of claim 54, wherein the extracellular vesicles have a diameter of about 30 nm to about 150 nm, preferably have a diameter of about 100 nm to about 115 nm.

77. The pharmaceutical composition of claim 54, wherein the extracellular vesicles are positive for CD9, CD81 and TSG101 and are negative for GM130.

78. The pharmaceutical composition of claim 54, wherein the extracellular-vesicles are exosomes.

79. The pharmaceutical composition of claim 54, wherein the MSCs are umbilical cord-derived mesenchymal stromal cells (UC-MSCs) and/or bone marrow-derived mesenchymal stromal cells (BM-MSCs).

80. The pharmaceutical composition of claim 54, wherein the MSCs are umbilical cord-derived mesenchymal stromal cells (UC-MSCs).

81. The pharmaceutical composition of claim 54, wherein the MSCs are positive for the surface markers CD73, CD90 and CD105, and optionally wherein the MSCs are negative for the surface markers CD14, CD19, CD34, CD45 and HLA-DR.

82. The pharmaceutical composition of claim 81, wherein the MSCs are positive for the cell surface markers and are negative for the cell surface markers when the extracellular-vesicles are isolated.

83. The pharmaceutical composition of claim 54, wherein the pharmaceutical composition or the extracellular vesicles is/are in a scaffold.

84. The pharmaceutical composition of claim 83, wherein the scaffold is a matrix.

85. The pharmaceutical composition of claim 84, wherein the matrix is selected of the group consisting of a ceramic implant, a polymer, hydrogel, bone matrix and demineralized bone matrix.

64. The pharmaceutical composition of 63, wherein the dose of the BMP is about 375 μ

g.

86. A method of treating a bone defect, a tendon defect or a spinal cord injury, wherein the method comprises the administration of a pharmaceutical composition comprising extracellular-vesicles derived from mesenchymal stromal cells (MSCs), wherein the extracellular-vesicles are essentially free of vesicles not derived from the MSCs, and wherein the extracellular-vesicles are essentially free of heparin.

87. The method according to claim 86, wherein the pharmaceutical composition comprises one or more Bone Morphogenic Proteins and/or PDGF, wherein the one or more Bone Morphogenic Protein(s) (BMP(s)) are selected from the group consisting of Bone Morphogenic Protein 2 (BMP2), Bone Morphogenic Protein 3 (BMP3), Bone Morphogenic Protein 4 (BMP4), Bone Morphogenic Protein 5 (BMP5), Bone Morphogenic Protein 6 (BMP6), Bone Morphogenic Protein 7 (BMP7), Bone Morphogenic Protein 8a (BMP8a), Bone Morphogenic Protein 8b (BMP8b), Bone Morphogenic Protein 12 (BMP12), Bone Morphogenic Protein 13 (BMP13), and Bone Morphogenic Protein 14 (BMP14).

88. The method according to claim 86, wherein the pharmaceutical composition comprises BMP2.

89. The method according to claim 86, wherein the pharmaceutical composition comprises BMP4.

90. The method according to claim 86, wherein the pharmaceutical composition comprises BMP6.

91. The method according to claim 86, wherein the pharmaceutical composition comprises BMP12.

92. The method according to claim 86, wherein the pharmaceutical composition comprises BMP13.

93. The method according to claim 86, wherein the pharmaceutical composition comprises BMP14.

94. The method according to claim 86, wherein the pharmaceutical composition comprises a dose of the one or more BMP(s).

95. The method according to claim 94, wherein the dose of the BMP(s) is between about 10 μ

g to about 10 mg.

96. The method according to claim 86, wherein the dose of the BMP is about 375 μ

g.

97. The method according to claim 96, wherein the pharmaceutical composition or the extracellular-vesicles is/are to be administered to the traumatic and/or disordered area.

98. The method according to claim 86, wherein the vesicles not derived from the MSCs are vesicles that are comprised in a culture medium prior to the culturing of the MSCs, such as vesicles that are comprised in serum, human platelet lysate, or plasma.

99. The method according to claim 86, wherein the vesicles not derived from the MSCs are vesicles that are comprised in a cell culture supplement, such as serum, human platelet lysate, or plasma.

100. The method according to claim 86, wherein the extracellular-vesicles comprise at least about 80%, 85%, 90%, 94.4%, 95%, 99% or 99.5% of extracellular-vesicles derived from the MSCs.

101. The method according to claim 86, wherein the extracellular-vesicles are essentially free of fibrinogen.

102. The method according to claim 86, wherein the extracellular-vesicles are derived from MSCs cultured in culture medium that is essentially free of vesicles not derived from the MSCs and that is essentially free of heparin, and preferably fibrinogen, or wherein the extracellular-vesicles are derived from MSCs cultured in medium that is essentially free of cell culture supplement, such as serum, human platelet lysate, or plasma.

103. The method according to claim 86, wherein the extracellular-vesicles are derived from MSCs cultured in culture medium, and wherein the fibrinogen and the vesicles were removed from the culture medium prior to the culturing of the MSCs, and preferably wherein said culture medium was supplemented with a cell culture supplement comprising vesicles.

104. The method according to claim 86, wherein the extracellular-vesicles comprise hsa-miR-146a-5p, hsa-miR-92a-3p, hsa-miR-21-5p, hsa-miR-148a-3p, hsa-miR-221-3p, hsa-let-7i-5p, and hsa-let-7f-5p.

105. The method according to claim 86, wherein the extracellular-vesicles are essentially free of hsa-miR-133, hsa-miR-135, hsa-miR-204, hsa-miR-211, hsa-miR-17, and hsa-miR-106.

106. The method according to claim 86, wherein the extracellular-vesicles comprise:

100% of hsa-miR-146a-5p,

at least about 50% of hsa-miR-92a-3p,

at least about 15% of hsa-miR-21-5p,

at least about 10% of hsa-miR-148a-3p,

at least about 15% of hsa-miR-221-3p,

at least about 5% of hsa-let-7i-5p, and

at least about 5% of hsa-let-7f-5p,

wherein the level of hsa-miR-146a-5p is set to 100%.

107. The method according to claim 86, wherein the extracellular-vesicles comprise:

100% of hsa-miR-146a-5p,

less than about 0.1% hsa-miR-133,

less than about 0.1% hsa-miR-135,

less than about 0.1% hsa-miR-204,

less than about 0.1% hsa-miR-211,

less than about 0.1% hsa-miR-17, and

less than about 0.1% hsa-miR-106,

wherein the level of hsa-miR-146a-5p is set to 100%.

108. The method according to claim 86, wherein the extracellular vesicles have a diameter of about 30 nm to about 150 nm, preferably have a diameter of about 100 nm to about 115 nm.

109. The method according to claim 86, wherein the extracellular vesicles are positive for CD9, CD81 and TSG101 and are negative for GM130.

110. The method according to claim 86, wherein the extracellular-vesicles are exosomes.

111. The method according to claim 86, wherein the MSCs are umbilical cord-derived mesenchymal stromal cells (UC-MSCs) and/or bone marrow-derived mesenchymal stromal cells (BM-MSCs).

112. The method according to claim 86, wherein the MSCs are umbilical cord-derived mesenchymal stromal cells (UC-MSCs).

113. The method according to claim 86, wherein the MSCs are positive for the surface markers CD73, CD90 and CD105, and optionally wherein the MSCs are negative for the surface markers CD14, CD19, CD34, CD45 and HLA-DR.

114. The method according to claim 113, wherein the MSCs are positive for the cell surface markers and are negative for the cell surface markers when the extracellular-vesicles are isolated.

115. The method according to claim 114, wherein the pharmaceutical composition or the extracellular vesicles is/are in a scaffold.

116. The method according to claim 115, wherein the scaffold is a matrix.

117. The method according to claim 116, wherein the matrix is selected of the group consisting of a ceramic implant, a polymer, hydrogel, bone matrix and demineralized bone matrix.

118. Extracellular-vesicles derived from mesenchymal stromal cells (MSCs), wherein the extracellular-vesicles are essentially free of vesicles not derived from the MSCs, and wherein the extracellular-vesicles are essentially free of heparin.

119. The extracellular-vesicles of claim 118, wherein the pharmaceutical composition or the extracellular-vesicles is/are to be administered to the traumatic and/or disordered area.

120. The extracellular-vesicles of claim 118, wherein the vesicles not derived from the MSCs are vesicles that are comprised in a culture medium prior to the culturing of the MSCs, such as vesicles that are comprised in serum, human platelet lysate, or plasma.

121. The extracellular-vesicles of claim 118, wherein the vesicles not derived from the MSCs are vesicles that are comprised in a cell culture supplement, such as serum, human platelet lysate, or plasma.

122. The extracellular-vesicles of claim 118, wherein the extracellular-vesicles comprise at least about 80%, 85%, 90%, 94.4%, 95%, 99% or 99.5% of extracellular-vesicles derived from the MSCs.

123. The extracellular-vesicles of claim 118, wherein the extracellular-vesicles are essentially free of fibrinogen.

124. The extracellular-vesicles of claim 118, wherein the extracellular-vesicles are derived from MSCs cultured in culture medium that is essentially free of vesicles not derived from the MSCs and that is essentially free of heparin, and preferably fibrinogen, or wherein the extracellular-vesicles are derived from MSCs cultured in medium that is essentially free of cell culture supplement, such as serum, human platelet lysate, or plasma.

125. The extracellular-vesicles of claim 118, wherein the extracellular-vesicles are derived from MSCs cultured in culture medium, and wherein the fibrinogen and the vesicles were removed from the culture medium prior to the culturing of the MSCs, and preferably wherein said culture medium was supplemented with a cell culture supplement comprising vesicles.

126. The extracellular-vesicles of claim 118, wherein the extracellular-vesicles comprise hsa-miR-146a-5p, hsa-miR-92a-3p, hsa-miR-21-5p, hsa-miR-148a-3p, hsa-miR-221-3p, hsa-let-7i-5p, and hsa-let-7f-5p.

127. The extracellular-vesicles of claim 118, wherein the extracellular-vesicles are essentially free of hsa-miR-133, hsa-miR-135, hsa-miR-204, hsa-miR-211, hsa-miR-17, and hsa-miR-106.

128. The extracellular-vesicles of claim 118, wherein the extracellular-vesicles comprise:

100% of hsa-miR-146a-5p,

at least about 50% of hsa-miR-92a-3p,

at least about 15% of hsa-miR-21-5p,

at least about 10% of hsa-miR-148a-3p,

at least about 15% of hsa-miR-221-3p,

at least about 5% of hsa-let-7i-5p, and

at least about 5% of hsa-let-7f-5p,

wherein the level of hsa-miR-146a-5p is set to 100%.

129. The extracellular-vesicles of claim 118, wherein the extracellular-vesicles comprise:

100% of hsa-miR-146a-5p,

less than about 0.1% hsa-miR-133,

less than about 0.1% hsa-miR-135,

less than about 0.1% hsa-miR-204,

less than about 0.1% hsa-miR-211,

less than about 0.1% hsa-miR-17, and

less than about 0.1% hsa-miR-106,

wherein the level of hsa-miR-146a-5p is set to 100%.

130. The extracellular-vesicles of claim 118, wherein the extracellular vesicles have a diameter of about 30 nm to about 150 nm, preferably have a diameter of about 100 nm to about 115 nm.

131. The extracellular-vesicles of claim 118, wherein the extracellular vesicles are positive for CD9, CD81 and TSG101 and are negative for GM130.

132. The extracellular-vesicles of claim 118, wherein the extracellular-vesicles are exosomes.

133. The extracellular-vesicles of claim 118, wherein the MSCs are umbilical cord-derived mesenchymal stromal cells (UC-MSCs) and/or bone marrow-derived mesenchymal stromal cells (BM-MSCs).

134. The extracellular-vesicles of claim 118, wherein the MSCs are umbilical cord-derived mesenchymal stromal cells (UC-MSCs).

135. The extracellular-vesicles of claim 118, wherein the MSCs are positive for the surface markers CD73, CD90 and CD105, and optionally wherein the MSCs are negative for the surface markers CD14, CD19, CD34, CD45 and HLA-DR.

136. The extracellular-vesicles of claim 135, wherein the MSCs are positive for the cell surface markers and are negative for the cell surface markers when the extracellular-vesicles are isolated.

137. The extracellular-vesicles of claim 118, wherein the pharmaceutical composition or the extracellular vesicles is/are in a scaffold.

138. The extracellular-vesicles of claim 137, wherein the scaffold is a matrix.

139. The extracellular-vesicles of claim 138, wherein the matrix is selected of the group consisting of a ceramic implant, a polymer, hydrogel, bone matrix and demineralized bone matrix.

140. A method for obtaining extracellular-vesicles derived from mesenchymal stromal cells (MSCs) that are essentially free of vesicles not derived from the MSCs, wherein the method comprises:

culturing the MSCs in a culture medium that is essentially free of vesicles not derived from the MSCs and that is essentially free of heparin and preferably fibrinogen; and

(ii) isolating the extracellular-vesicles derived from the MSCs from the culture medium.

141. The method of claim 140, wherein the vesicles not derived from the MSCs are vesicles that are comprised in the culture medium prior to the culturing step (i).

142. The method of claim 140, wherein the vesicles not derived from the MSCs are vesicles that are comprised in the serum, human platelet lysate, or plasma.

143. The method of claim 140, wherein the culture medium is medium that does not comprise a cell culture supplement, such as serum, human platelet lysate, or plasma.

144. A method for obtaining extracellular-vesicles derived from mesenchymal stromal cells (MSCs), wherein the method comprises:

(i) removing fibrinogen from a culture medium, wherein no heparin is added to the culture medium, and removing vesicles from the culture medium,

(ii) culturing the MSCs in the culture medium of step (i), and

(iii) isolating the extracellular-vesicles derived from the MSCs from the medium.

145. The method of claim 144, wherein the MSCs are cultured in the medium for at least about 48 hours.

146. Extracellular-vesicles obtained according to claim 144.

147. The extracellular-vesicles of claim 146, wherein the extracellular-vesicles are derived from mesenchymal stromal cells (MSCs), wherein the extracellular-vesicles are essentially free of vesicles not derived from the MSCs, and wherein the extracellular-vesicles are essentially free of heparin.

148. The extracellular-vesicles of claim 146, wherein the extracellular-vesicles comprise hsa-miR-146a-5p, hsa-miR-92a-3p, hsa-miR-21-5p, hsa-miR-148a-3p, hsa-miR-221-3p, hsa-let-7i-5p, and hsa-let-7f-5p.

149. The extracellular-vesicle of claim 146, wherein the extracellular-vesicles are derived from mesenchymal stromal cells (MSCs), wherein the extracellular-vesicles comprise at least about 80%, 85%, 90%, 94.4%, 95%, 99% or 99.5% of extracellular-vesicles derived from the MSCs.

150. Mesenchymal stromal cells (MSCs) comprised and/or cultured in a culture medium that is essentially free of vesicles not derived from the MSCs, and preferably wherein the culture medium is essentially free of heparin and preferably fibrinogen.

151. The mesenchymal stromal cells of claim 150, wherein the fibrinogen and the vesicles comprised in the culture medium prior to the culturing of the MSCs were removed, and preferably wherein the culture medium was supplemented with a cell culture supplement comprising vesicles.

152. A culture medium, wherein the culture medium comprises extracellular-vesicles derived from mesenchymal stromal cells (MSCs), and wherein the extracellular-vesicles are essentially free of vesicles not derived from the MSCs, and preferably wherein the culture medium is essentially free of heparin and preferably fibrinogen.

153. The culture medium of claim 152, wherein the fibrinogen and the vesicles comprised in the culture medium prior to culturing the MSCs were removed, and preferably wherein the culture medium was supplemented with a cell culture supplement comprising vesicles.